Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Early Phase 1Not Yet RecruitingNCT06932861

Xinxin Zhang5 enrolled

Overview

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Rhabdomyosarcoma

Interventions

mRNA Tumor Vaccine TherapyBIOLOGICAL

personalized mRNA vaccines

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing; 2. Age ≥ 6 years; 3. No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life; 4. Expected survival time greater than 6 months; 5. ECOG performance status score of 0-1; - Exclusion Criteria: * 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.

Outcomes

Primary Outcomes

Adverse Event

Time frame: From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first.

Central Contacts

Xinxin Zhang

CONTACT

+86 15910520109 xinxinzhang66@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.